Animal tests of an expected COVID-19 vaccine being developed by Chinese researchers demonstrate it triggers an immune reaction against the novel coronavirus, offering some promise since it goes into early-stage human trials, according to a peer-reviewed study.

ARCoV is a messenger RNA vaccine which uses technology like applicants being manufactured by Moderna and BioNtech and Pfizer. It is the 2nd possible COVID-19 vaccine which China's military-backed research unit has transferred into clinical trials.

Results of trials of ARCoV in monkeys and mice, printed in the peer-reviewed clinical journal Cell on Thursday, show both and two-dose inoculations induced strong antibody and T-cell responses against several COVID-19-causing virus strains.

Nevertheless, researchers conducting the trial cautioned that they were not yet able to realize the length of time the ARCoV-induced Compounds might last or how strong their defense could be to other breeds that cause COVID-19 but were not examined in the research.

ARCoV is secure at 25°C (77°F) for at least a week, researchers said, which might make it more attractive for possible immunisation campaigns in hard-to-reach inhabitants in places where cold-chain storage and transport aren't always dependable.

While no COVID-19 vaccine was approved for sale yet, more than 150 have been in development globally with an aim to help finish the global pandemic which has claimed over 600,000 lives. But whether any will triumph remains far from clear.